Premarket analyst action - healthcare

• UBS has been busy. New Buy ratings: Alexion Pharmaceuticals (NASDAQ:ALXN)/PT $138 (14% upside); AveXis (NASDAQ:AVXS)/PT $95 (28% upside); Esperion Therapeutics (NASDAQ:ESPR)/PT $52 (50% upside); Spark Therapeutics (NASDAQ:ONCE)/PT $70 (31% upside). New Neutral Ratings: Alnylam (NASDAQ:ALNY)/PT $55 (4% upside); BioMarin Pharmaceutical (NASDAQ:BMRN)/PT $92 (3% upside). Selecta Biosciences (NASDAQ:SELB) reiterated with Buy rating and $26 (86% upside) PT. United Therapeutics (NASDAQ:UTHR) initiated with Sell rating and $112 (19% downside risk) price target.
• Galectin Therapeutics (NASDAQ:GALT) upgraded to Buy with a $3.50 (77% upside) price target by H.C. Wainwright.
• Hologic (NASDAQ:HOLX) resumed at Outperform with a $52 (20% upside) price target by Leerink Swann.
• NewLink Genetics (NASDAQ:NLNK) upgraded to Buy with a $30 (36% upside) price target by SunTrust.